Results 51 to 60 of about 3,487 (207)

Table_2_Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course.DOCX

, 2022
BackgroundMyelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS.
Omri Zveik (12283328), Ariel Rechtman (12283325), Benjamin Uliel (12283331), Atira S. Bick (12283337), Livnat Brill (3425690), Adi Vaknin-Dembinsky (110061), Netta Levin (711894), Nitzan Haham (12283334)   +7 more
core   +1 more source

Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course

Frontiers in Neurology, 2022
BackgroundMyelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS.
Ariel Rechtman, Livnat Brill, Omri Zveik, Benjamin Uliel, Nitzan Haham, Atira S. Bick, Netta Levin, Adi Vaknin-Dembinsky   +7 more
doaj   +1 more source

Altered lipidomic and metabolomic status in cerebrospinal fluid of children with myelin oligodendrocyte glycoprotein antibody-associated disorder

Biochemistry and Biophysics Reports
Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a group of acquired demyelinating syndromes affecting the central nervous system. MOGAD-associated bioactive molecules remain elusive.
Pin Fee Chong, Kenta Kajiwara, Yuji Ueno, Satoshi Akamine, Hiroyuki Torisu, Ryutaro Kira, Shouichi Ohga, Yasunari Sakai   +7 more
doaj   +1 more source

Image_2_Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course.TIF

, 2022
BackgroundMyelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS.
Omri Zveik (12283328), Ariel Rechtman (12283325), Benjamin Uliel (12283331), Atira S. Bick (12283337), Livnat Brill (3425690), Adi Vaknin-Dembinsky (110061), Netta Levin (711894), Nitzan Haham (12283334)   +7 more
core   +1 more source

MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity

JCI Insight, 2023
Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) is an inflammatory demyelinating CNS condition characterized by the presence of MOG autoantibodies.
Soumya S. Yandamuri, Beata Filipek, Abeer H. Obaid, Nikhil Lele, Joshua M. Thurman, Naila Makhani, Richard J. Nowak, Yong Guo, Claudia F. Lucchinetti, Eoin P. Flanagan, Erin E. Longbrake, Kevin C. O’Connor   +11 more
doaj   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

The “H sign” in MOGAD myelitis

Neurological Sciences
Abstract A 40-year-old man presented with acute urinary retention and bilateral lower limb weakness. MRI revealed a longitudinally extensive T2 hyperintense spinal cord lesion from C6 to T10, predominantly involving the gray matter (“H sign”). Brain MRI and CSF studies were unremarkable. Serum MOG-IgG was positive.
Santiago Aristizabal Ortiz, Laura Andrea Campaña Perilla, Angela Patricia Guarnizo Capera   +2 more
openaire   +2 more sources

Table_3_Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course.DOCX

, 2022
BackgroundMyelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS.
Omri Zveik (12283328), Ariel Rechtman (12283325), Benjamin Uliel (12283331), Atira S. Bick (12283337), Livnat Brill (3425690), Adi Vaknin-Dembinsky (110061), Netta Levin (711894), Nitzan Haham (12283334)   +7 more
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Table_5_Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course.DOCX

, 2022
BackgroundMyelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS.
Omri Zveik (12283328), Ariel Rechtman (12283325), Benjamin Uliel (12283331), Atira S. Bick (12283337), Livnat Brill (3425690), Adi Vaknin-Dembinsky (110061), Netta Levin (711894), Nitzan Haham (12283334)   +7 more
core   +1 more source